Cytora Overview
Cytora is on a mission to make it standard practice for people to be treated with off-the-shelf (allogeneic) Stem Cell medicines, derived from the readily accessible oral mucosa termed human oral mucosa stem cells - hOMSC, for some of the toughest diseases within this decade, including Parkinson’s, Multiple System Atrophy (MSA), Alzheimer’s Dementia, and non-healing diabetic wounds (IDFU). Cytora is a portfolio company of Galil Ofek Innovations, a peripheral technology incubator focused primarily on biomedical technologies such as medical devices.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
/PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today...
Cytora, a clinical stage biopharmaceutical company, announced successful results from its Phase 1/2a clinical trial for hOMSC200, a stem cell therapy targeting diabetic foot ulcers (DFUs). The trial demonstrated that hOMSC200 is safe and significantly more effective than standard care, with no immune response in patients. The study involved 21 subjects and showed a higher wound closure rate in the treatment group compared to placebo. Cytora plans to apply for an IND in 2025 to initiate a larger Phase 2 trial in 2026. The companys technology is based on human Oral Mucosa Stem Cells, which have shown promise in treating chronic wounds and degenerative diseases.
Product StageFDA approved/pending approval
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2M |
| Last funding | $2M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.cytorastem.com/ |
Locations
Arieh Ben Eliezer Street 46, Ramat Gan, Israel
Photos & Videos
No files yet
